Marmara University

marmara.edu.tr

Total trials

545

Active

101

Phase 3

2

Total enrollment

84,534

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Romosozumab and Denosumab Combination Therapy1
Romosozumab Prefilled Syringe [Evenity]1
Denosumab1
Rivaroxaban plus immunosupression1
propofol3
Sevofluorane1
Phenol1
Opioid-free Anesthesia1
Opioid based Anesthesia1
Tociliuzumab1
Infliximab1
Adalimumab1
Certolizumab Pegol1

Next readouts

  • 2025-11
  • 2026-10-15
  • 2026-12-09
  • 2027-04-01
  • 2027-10-01
  • 2027-12-15

Top conditions

  • Cerebral Palsy15
  • Pain12
  • Stroke12
  • Periodontitis11
  • Anxiety10
  • Central Sensitisation9
  • Postoperative Pain8
  • Lumbar Disc Herniation7

Frequently asked questions about Marmara University

How many clinical trials does Marmara University have on ClinicalTrials.gov?
Marmara University is listed as the lead sponsor on 545 clinical trials in ClinicalTrials.gov, 101 of which are currently active (recruiting, enrolling, or ongoing).
How many of Marmara University's trials are in Phase 3?
2 of Marmara University's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Marmara University focus on?
Marmara University's most-studied conditions on ClinicalTrials.gov are Cerebral Palsy, Pain, Stroke, Periodontitis, Anxiety.
When are Marmara University's next clinical trial readouts?
Marmara University has 6 upcoming primary-completion readouts tracked here; the soonest is “Comparison of Ganglion Impar Radiofrequency Ablation and Phenol Neurolysis Techniques for Chronic Coccydynia Treatment”, expected around 2025-11.